Acceleron Announces Departure of Chief Medical Officer
05 Abril 2019 - 2:01PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare diseases, announced that
Robert K. Zeldin, M.D., Chief Medical Officer, is no longer
employed by the company, as of today. The company has begun an
executive search for his replacement.
“We thank Robert for his contributions to the Company over the
last 9 months and wish him the best in his future endeavors,” said
Habib Dable, President and Chief Executive Officer of
Acceleron.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. The Company's leadership in the
understanding of TGF-beta biology and protein engineering generates
innovative compounds that engage the body's ability to regulate
cellular growth and repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular program with ACE-083,
a locally-acting Myostatin+ agent in Phase 2 development in
facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth
disease and is conducting a Phase 2 pulmonary program with
sotatercept in pulmonary arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190405005396/en/
Acceleron Pharma Inc.Investors:Todd James, IRC, (617)
649-9393Vice President, Investor Relations and Corporate
CommunicationsorMedia:Matt Fearer, (617) 301-9557Director,
Corporate Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024